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Objectives: To examine whether the overall results of the CASTLE study pertain to both genders, we analysed the
efﬁcacyand safetyof atazanavir/ritonavirand lopinavir/ritonavir in 277 female and 606 male patients in the open-
label, multinational trial over 96 weeks. The trial is registered with ClinicalTrials.gov, number NCT00272779.
Methods: Treatment-naive patients aged ≥18 years with HIV-1 RNA ≥5000 copies/mL were randomized to
receive either atazanavir/ritonavir 300/100 mg once daily or lopinavir/ritonavir 400/100 mg twice daily, with
ﬁxed-dose tenofovir/emtricitabine 300/200 mg once daily.
Results: At week 96, conﬁrmed virological response rates (HIV RNA ,50 copies/mL; intent-to-treat analysis) were
higher in women and men receiving atazanavir/ritonavir than those receiving lopinavir/ritonavir and lower in
women than men in both treatment arms (67% of women and 77% of men on atazanavir/ritonavir and 63%
of women and 71% of men on lopinavir/ritonavir). These differences were not observed in the on-treatment
analysis. Mean change in CD4 cell count from baseline to week 96 was 265 cells/mm
3 for women and
269 cells/mm
3 for men on atazanavir/ritonavir and 298 cells/mm
3 for women and 286 cells/mm
3 for men on lopi-
navir/ritonavir. Discontinuation rates were higher in women than men in each treatment arm (22% of women and
15% of men on atazanavir/ritonavir and 29% of women and 18% of men on lopinavir/ritonavir). In women and
men, grade 2–4 nausea and diarrhoea were more frequent in the lopinavir/ritonavir group; jaundice and hyperbi-
lirubinaemia occurred more frequently in the atazanavir/ritonavir group.
Conclusions: Once-daily atazanavir/ritonavir is an effective and well-tolerated therapeutic option for women and
men with HIV-1 infection. The sex-based differences in response may be due to higher discontinuation rates in
women.
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Introduction
Of the estimated 35 million people living with HIV, almost half
are women, and this proportion is increasing in several
countries.
1,2 Of particular concern are the increases in HIV infec-
tion among young women, who now make up .60% of young
adults aged 15–24 years living with HIV/AIDS.
1 Women
account for  25% of new AIDS cases and more than one-third
of new HIVdiagnoses in the USA. African–American and Hispanic
women represent a disproportionate percentage of the disease
burden, constituting ,25% of all US women, but accounting
for 79% of new diagnoses.
3 Despite the changing epidemiology
of HIV among women, they remain under-represented in most
clinical HIV studies as few women enrol and continue in trials
in the developed world.
4,5 Much of the data available on
women with HIV are from studies carried out in resource-limited
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363settings. In addition, as most clinical studies have enrolled fewer
women than men, treatment guidelines are based primarily on
outcomes in men.
Recent studies highlight that despite initial concerns regarding
potential differences in response to antiretroviral (ARV) therapy
across gender, both men and women respond equally well to
therapy. Differences in response typically occur due to a higher
number of discontinuations among women as compared with
men. When efﬁcacy results are censored for discontinuations
other than virological failure, women have responded as well as
men in several clinical trials in both treatment-naive and
treatment-experienced HIV-infected patients.
3,6–9 The reasons for
the high number of discontinuations among women in HIV clinical
trials are not known. Even though there do not appear to be signiﬁ-
cant differences in efﬁcacy by sex, gender differences in toxicity and
adverse reactions have been detected, despite the fact that no
major study in treatment-naive patients has been designed or
powered to detect gender differences.
5,6,8,10–13 As there are
several issues that women must consider when incorporating a
complex ARV regimen into their lives (including contraception, child-
bearing, breastfeeding and the potential for mother-to-child HIV
transmission), it is imperative to deﬁne potential side effects that
may affect the choice of treatment regimen.
3,14 HIV stigma and
access to care may also affect outcomes for HIV-infected
women.
3,15 For many women, ﬁtting modern regimens and clinic
visits into their busy schedules can be a challenge. Therefore, tailor-
ing ARV treatment regimens to gender may optimize response, tol-
erability and adherence, and minimize toxicity.
Analyses from the open-label, international CASTLE study
provide much-needed data on the efﬁcacy and tolerability of pro-
tease inhibitor (PI)-based regimens in female and male patients.
Findings from a 48 week analysis, reported at the Seventeenth
International AIDS Conference (2008), demonstrated that
treatment-naive women receiving atazanavir/ritonavir or lopina-
vir/ritonavir (both in combination with tenofovir/emtricitabine)
experienced a greater number of treatment-related adverse
events and slightly lower virological response than males.
8
These data are consistent with the gender-based differences pre-
viously noted; however, these analyses were not preplanned or
powered to identify differences in efﬁcacy and safety. We
report here results from an analysis assessing the efﬁcacy,
safety and tolerability of atazanavir/ritonavir and lopinavir/rito-
navir in combination with tenofovir/emtricitabine in female and
male patients enrolled in the CASTLE study through 96 weeks
of treatment. In the overall CASTLE population, atazanavir/rito-
navir was shown to be non-inferior to, with higher virological
response rates than, lopinavir/ritonavir through 96 weeks of
treatment. The difference in response rates in favour of atazana-
vir/ritonavir at 96 weeks was driven by a higher rate of discon-
tinuation among patients receiving lopinavir/ritonavir. This was
accompanied, in the overall population, by signiﬁcantly less
lipid elevation and better gastrointestinal tolerability in the ata-
zanavir/ritonavir group than in the lopinavir/ritonavir group.
16,17
Methods
Study design and participants
Details of the study design and participants were described previously
by Molina et al.
17 Brieﬂy, patients were eligible for enrolment if they
were infected with HIV-1, were aged ≥18 years, were naive to ARV
therapy (,1 week previous ARV experience or ,6 weeks exposure for
prophylaxis or prevention of mother-to-child transmission) and had
HIV-1 RNA ≥5000 copies/mL. Patients were randomized to receive
either atazanavir/ritonavir 300/100 mg once daily or lopinavir/ritonavir
400/100 mg twice daily, each given in combination with ﬁxed-dose teno-
fovir/emtricitabine 300/200 mg once daily. Patients assigned to lopinavir/
ritonavir were able to switch from the soft-gel capsule to the tablet for-
mulation after 48 weeks. Randomization was in a 1:1 ratio, and was stra-
tiﬁed for HIV-1 level (,100000 or ≥100000 copies/mL) and geographical
region.
Research ethics
The study was conducted in accordance with good clinical practice and
the ethical principles of the Declaration of Helsinki. The institutional
review board/independent ethics committee at each study site approved
the protocol, amendments and informed consent before initiation. The
trial is registered with ClinicalTrials.gov, number NCT00272779.
Procedures
Study procedures were outlined in the previous publication
17 and contin-
ued as described for the duration of the 96 week study. Patients were
assessed at screening, day 1 (baseline) and at weeks 2, 4, 12, 24, 36,
48, 60, 72, 84 and 96, or at early termination. Vital signs and samples
for plasma HIV RNA, CD4 cell count and laboratory tests (serum
chemistry and haematology, fasting lipid proﬁle, urinalysis, hepatitis
co-infection) were taken at all patient visits (except week 2).
The primary endpoint of the CASTLE study was the the proportion of
patients with HIV-1 RNA ,50 copies/mL at week 48, as reported by
Molina et al.
16 In this paper, secondary efﬁcacy endpoints for patients
of female and male gender are reported, including the proportion of
patients with HIV-1 RNA ,50 copies/mL at week 96 and change in absol-
ute CD4 cell count from baseline through week 96. Safety endpoints
assessed at week 96 included frequency of adverse events, serious
adverse events and discontinuation due to adverse events, and
changes from baseline in fasting lipids over time.
Statistical analysis
Statistical methods for the week 96 analysis have been previously pub-
lished
17 and are brieﬂy summarized below. Efﬁcacy results are presented
by the as-randomized treatment regimen [intent-to-treat (ITT)]. Safety
results are presented by the as-treated treatment regimen (i.e. by the
treatment regimen actually received). The gender analysis was not
powered to detect statistical differences, and no statistical comparisons
between treatment arms or between genders were carried out for
this report. The proportion of patients with HIV RNA ,50 copies/mL at
week 96 was assessed with several algorithms and cohorts of random-
ized patients. The principal analysis was based on the conﬁrmed viro-
logical response (CVR) non-completer¼failure (NC¼F; ITT) deﬁnition of
response. Supportive analyses used the virological response-observed
cases (VR-OC) deﬁnitions of response and a post hoc cross-sectional
analysis at week 96 in the as-treated population. Observed values were
used to summarize CD4 cell counts and their changes from baseline
through week 96.
Categories of fasting lipid parameters were tabulated through week
96 using observed values. Categories for cholesterol and triglycerides
were deﬁned according to the US National Cholesterol Education
Program (NCEP) Adult Treatment Panel (ATP) III guidelines.
18 Analyses
of fasting lipids over time excluded values obtained after patients com-
menced lipid-lowering agents.
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Disposition and baseline data
Of the 883 HIV-infected, treatment-naive patients randomized
within CASTLE, 277 (31%) were female and 606 (69%) were
male. Few women from developed nations were enrolled in the
CASTLE study; 6% of women were from North America, com-
pared with 48% from South America and 27% from Africa.
Other baseline characteristics for female and male patients
were comparable across the two treatment arms (Table 1).
Thirty-one (22%) women in the atazanavir/ritonavir group
and 40 (29%) women in the lopinavir/ritonavir group discontin-
ued through week 96 (Figure 1). Discontinuation rates were
lower for male patients; 15% and 18% in the atazanavir/ritonavir
and lopinavir/ritonavir groups, respectively. The reasons for dis-
continuation were similar between the two treatment groups.
However, more women in the lopinavir/ritonavir group than in
the atazanavir/ritonavir group withdrew as a result of suboptimal
adherence (eight versus four) or withdrawn consent (nine versus
three). Other common reasons for discontinuation were adverse
events, lack of efﬁcacy and pregnancy (Figure 1). Adverse events
had only a minor inﬂuence on discontinuation rates for both
treatment groups, with six (4%) women in each group, seven
(2%) men in the atazanavir/ritonavir group and 16 (5%) men
in the lopinavir/ritonavir group withdrawing before week 96 for
this reason.
Efﬁcacy
In the CVR analysis (NC¼F; ITT), 67% of women and 77% of men
receiving atazanavir/ritonavirand 63% of women and 71% of men
receiving lopinavir/ritonavir achieved HIV-1 RNA ,50 copies/mL at
96 weeks of treatment (Figure 2). CVR rates were generally lower
in female patients than male patients in both treatment arms.
Virological response rates in the VR-OC analysis were comparable
between treatment groups and between genders (86% of women
and 91% of men on atazanavir/ritonavir and 89% of women and
87% of men on lopinavir/ritonavirachieved HIV-1 RNA ,50 copies/
mL) at 96 weeks of treatment (Figure 2). Response rates (HIV RNA
,50 copies/mL) by cross-sectional analysis at 96 weeks in the
as-treated population were 69% (95/138) of female patients
and 77% (234/303) of male patients for atazanavir/ritonavir and
63% (88/139) of female patients and 70% (210/298) of male
patients for lopinavir/ritonavir.
The mean change in CD4 cell count from baseline to week 96
was similar between the two treatment groups, at 265 cells/mm
3
in female patients and 269 cells/mm
3 in male patients on
atazanavir/ritonavir and 298 cells/mm
3 in female patients and
286 cells/mm
3 in male patients on lopinavir/ritonavir.
Safety
Eight hundred and seventy-eight subjects received study drug
and were included in safety analyses. Three subjects were ran-
domized to lopinavir/ritonavir but received atazanavir/ritonavir
during the entire treatment period. No unexpected adverse
events occurred, and adverse events were not treatment limiting
in most cases. Two (1%) deaths occurred among women in the
study, both in the lopinavir/ritonavir group. Four men (1%) in the
lopinavir/ritonavir group and six men (2%) in the atazanavir/
ritonavir treatment group died during the study. None of the
deaths were considered to be related to the study drugs.
Serious adverse events were reported by 20 (14%) women and
43 (14%) men in the atazanavir/ritonavir group and 17 (12%)
women and 33 (11%) men in the lopinavir/ritonavir group. All
but a few serious adverse events were reported by ,1% of the
population. There were no reports of myocardial infarction in
either treatment group.
Table 1. Baseline characteristics and demographics for female and male patients randomized in CASTLE
ATV/RTV, N¼440 LPV/RTV, N¼443
female, n¼138 male, n¼302 female, n¼139 male, n¼304
Age, median years (min, max) 33 (20, 56) 35 (19, 72) 37 (19, 63) 36 (19, 71)
Region, n (%)
Africa 33 (24) 34 (11) 41 (29) 24 (8)
Asia 15 (11) 24 (8) 12 (9) 28 (9)
Europe 15 (11) 50 (17) 13 (9) 53 (17)
North America 7 (5) 60 (20) 9 (6) 60 (20)
South America 68 (49) 134 (44) 64 (46) 139 (46)
CDC class C AIDS, n (%) 4 (3) 15 (5) 5 (4) 19 (6)
HIV RNA log10 copies/mL, median (min, max) 4.87 (2.60, 5.88) 5.06 (3.05, 5.88) 4.87 (3.69, 5.88) 5.00 (3.32, 5.88)
HIV RNA ≥100000 copies/mL, n (%) 56 (41) 169 (56) 57 (41) 151 (50)
CD4 cells/mm
3, median (min, max) 196 (8, 794) 208 (2, 760) 190 (11, 416) 210 (4, 810)
CD4 ,50 cells/mm
3, n (%) 15 (11) 43 (14) 15 (11) 33 (11)
Hepatitis B and/or C co-infection, n (%) 15 (11) 46 (15) 11 (8) 40 (13)
ATV, atazanavir; LPV, lopinavir; RTV, ritonavir.
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JAC883 patients randomized
443 patients allocated to lopinavir/ritonavir 440 patients allocated to atazanavir/ritonavir
138 women 302 men
138 Treated 300
31 (22%) Discontinuations 45 (15%)
8 (6%) Lack of efﬁcacya 8 (3%)
6 (4%)b Adverse event 7 (2%)c
5 (4%) Pregnancyf 0
4 (3%) Poor/non-
compliance
8 (3%)
3 (2%) Withdrew
consent
2 (<1%)
1 (<1%) No longer meets
study criteria
3 (<1%)
2 (1%)g Discontinued at
week 96
2 (<1%)h
2 (1%) Lost to follow-up 8 (3%)
0 Death 6 (2%)
0 Other 1 (<1%)
139 women 304 men
139 Treated 301
40 (29%) Discontinuations 55 (18%)
6 (4%) Lack of efﬁcacya 4 (1%)
6 (4%)d Adverse event 16 (5%)e
7 (5%) Pregnancyf 0
8 (6%) Poor/non-
compliance
8 (3%)
9 (6%) Withdrew
consent
9 (3%)
0 No longer meets
study criteria
3 (<1%)
0 Discontinued at
week 96
0
1 (<1%) Lost to follow-up 12 (4%)
2 (1%) Death 3 (<1%)
1 (<1%) Other 0
Figure 1. Trial proﬁle for female and male patients in the CASTLE study.
aInsufﬁcient viral load response determined by investigators.
bTwo cases of
rash, one case of tuberculosis (TB), one case of thrombocytopenia, one gastrointestinal problem and one gastrointestinal problem plus dizziness,
jaundice, hepatomegaly and hyperbilirubinaemia.
cTwo cases of jaundice, two gastrointestinal problems, one case of abdominal pain, one case of
Mycobacterium infection and one case of Fanconi syndrome.
dTwo cases of TB, one case of hypersensitivity, one case of hypertrophic
cardiomyopathy, one case of rash and one case of proteinuria.
eSeven cases of diarrhoea, one case of furnicle, one case of major depression, one
case of rash, one case of rhabdomycosis, one case of lipoma, two cases of hyperlipidaemia, one case of lipodystrophy and one case of Kaposi’s
sarcoma.
fProtocol-deﬁned for discontinuation.
gOne pregnancy and one poor/non-compliance.
hOne lost to follow-up and one poor/non-compliance.
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treatment-related adverse event was identical in both treatment
groups, at 33% (Table 2). Twenty-nine percent of men in the ata-
zanavir/ritonavir arm and 32% of men in the lopinavir/ritonavir-
treatment arm experienced grade 2–4 treatment-related
adverse events. Grade 2–4 treatment-related nausea and
diarrhoea were more common among women and men in the
lopinavir/ritonavir group than in the atazanavir/ritonavir group;
however, jaundice/scleral icterus and hyperbilirubinaemia
occurred more frequently in women and men receiving atazana-
vir/ritonavir than in those receiving lopinavir/ritonavir. Grade 2–4
treatment-related rash occurred in 5% and 3% of women and
2% and 2% of men receiving atazanavir/ritonavir and lopinavir/
ritonavir, respectively.
Figure 3 shows that the mean percentage changes in fasting
lipid concentrations over 96 weeks were generally greater in
women and men receiving lopinavir/ritonavir than in those
receiving atazanavir/ritonavir. In the atazanavir/ritonavir arm,
mean changes from baseline in all lipid parameters were lower
in women than in men. In the lopinavir/ritonavir arm, mean
changes from baseline were lower in women than in men for
non-high-density lipoprotein (non-HDL) cholesterol and triglycer-
ides, higher for women than men for HDL cholesterol and similar
in women and men for total cholesterol and low-density lipo-
protein (LDL) cholesterol. More women and men receiving
lopinavir/ritonavir (9%) than atazanavir/ritonavir (2%) initiated
lipid-lowering therapy after the start of study therapy. Women
and men in both treatment groups had optimal median fasting
total cholesterol, HDL cholesterol, non-HDL cholesterol and LDL
cholesterol concentrations at week 96 as deﬁned by the NCEP
ATP III guidelines. Men receiving lopinavir/ritonavir had median
fasting triglyceride concentrations (177 mg/dL) above the NCEP
ATP III guidelines at 96 weeks.
Discussion
The ﬁndings of this analysis of response to therapy across male
and female genders were consistent with the overall results for
the CASTLE study.
17 In the ITT analysis, women and men
Table 2. Selected grade 2–4 treatment-related adverse events in female and male patients in each treatment group through week 96
Adverse events, n (%)
ATV/RTV LPV/RTV
female, n¼138 male, n¼303 female, n¼139 male, n¼298
Any adverse event 45 (33) 88 (29) 46 (33) 94 (32)
Nausea 10 (7) 8 (3) 19 (14) 14 (5)
Diarrhoea 4 (3) 7 (2) 13 (9) 41 (14)
Hyperbilirubinaemia
a 15 (11) 29 (10) 1 (,1) 1 (,1)
Jaundice/scleral icterus 6 (4) 15 (5) 0 0
Rash
b 7 (5) 7 (2) 4 (3) 6 (2)
Vomiting 2 (1) 3 (,1) 3 (2) 4 (1)
ATV, atazanavir; LPV, lopinavir; RTV, ritonavir.
aHyperbilirubinaemia also includes blood bilirubin abnormal, blood bilirubin increased, blood bilirubin unconjugated and blood bilirubin unconjugated
increased from the INVESTIGATIONS system organ class.
bRash includes dermatitis allergic, prurigo, psoriasis, rash, rash erythematous, rash generalized, rash maculopapular, rash papular, rosacea and
urticaria.
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JACreceiving atazanavir/ritonavir had higher virological response
rates than those receiving lopinavir/ritonavir, and women in
either treatment arm had lower virological response rates than
men. Through 96 weeks of treatment, gastrointestinal tolerability
was better and there was less elevation of lipids among women
and men receiving atazanavir/ritonavir than those receiving lopi-
navir/ritonavir, which is similar to the trend observed in the
overall population.
17 It is possible that increased gastrointestinal
toxicity contributed to the higher rate of treatment discontinu-
ation in the lopinavir/ritonavir group; however, this requires
further investigation.
The virological responses observed in the 96 week CASTLE
study are comparable to those reported for other studies of ata-
zanavir/ritonavir
19,20 and lopinavir/ritonavir
21,22 after taking into
account the different study designs and subjects. The ﬁndings
are also consistent with those reported for studies of other
PIs.
6,21–24 Findings from our CVR analysis suggest that the efﬁ-
cacy of atazanavir/ritonavir and lopinavir/ritonavir may be
lower in women than in men. However, these differences were
not observed in the VR-OC on-treatment analysis, which
showed that all observed virological response rates were com-
parable between treatment groups and between genders after
96 weeks of treatment. These ﬁndings are consistent with the
overall results for the CASTLE study in which the difference in
response between treatment arms in the ITT analysis at
96 weeks was driven by a similar virological response rate with
a higher rate of discontinuation among patients receiving
lopinavir/ritonavir.
17 In this analysis, the difference in virological
response observed between genders in the ITT analysis at
96 weeks may have been due to the higher rate of discontinu-
ation among women than among men in each treatment arm.
Similar differences in response to once- or twice-daily lopinavir/
ritonavir and tenofovir/emtricitabine between men and women
have been reported,
25 while other studies have found no gender-
related differences in response rates to fosamprenavir/ritonavir
26
and darunavir/ritonavir
6,27 in treatment-naive patients or combi-
nation ARV regimens in general.
28
In our study, a greater proportion of women than men dis-
continued the study before week 96 in both treatment groups,
a trend that has also been observed in previous studies.
5–9
This difference in the rate of discontinuation was partly driven
by pregnancy (4%–5%) among women in both treatment
groups. In addition, more women (6%) than men (3%) discontin-
ued due to suboptimal adherence in the lopinavir/ritonavir arm.
Whether the difference in compliance between women in the
two treatment arms and between women and men is related
to the higher rate of gastrointestinal side effects with lopinavir/
ritonavir is unknown. There are several factors that may inﬂu-
ence women’s compliance with HIV regimens, including busy
daily schedules, childcare responsibilities, social relationships,
emotional well-being and therapy-induced changes in body
appearance, such as weight gain.
29
It is not known why women discontinue clinical trials more
frequently than men. The Gender, Race and Clinical Experience
(GRACE) study, which assessed darunavir/ritonavir (plus
investigator-selected background regimens) in 287 and 142
treatment-experienced HIV-infected men and women, respect-
ively, found a similar trend. At 48 weeks there was a higher-
than-expected rate of discontinuation due to loss of follow-up,
relocation and withdrawal of consent.
5 Although the numbers
of women in clinical trials is increasing, their numbers remain
low at only 20% in the AIDS Clinical Trials Group (ACTG5142)
study,
30 22% in the KLEAN study,
21 30% in the ARTEMIS
study
22 and 31% in the CASTLE study.
16
There are several factors exclusive to women that may inﬂu-
ence the decision to enrol in, or continue to participate in, a clini-
cal study. Women of childbearing potential need to consider
what contraception they would use when participating in clinical
studies as few ARV drugs are indicated for concomitant use with
contraceptive drugs.
3,31–33 Several PIs may increase or decrease
the levels of contraceptives and may result in adverse events.
14
The potential teratogenic risk if pregnancy should occur may also
deter women from enrolling or continuing in clinical studies.
Nonetheless, for HIV-infected women who want to become
pregnant, ARV therapy can reduce the risk of mother-to-child
HIV transmission.
3,14 HIV-infected women are also more likely
to have ﬁnancial problems or experience discrimination than
HIV-infected men and this may inﬂuence a woman’s willingness
to participate in a clinical study.
34 However, most of these data
are obtained from studies carried out in the developing world.
Until more women from the developed world participate in clini-
cal studies, the reasons for fewer enrolments and more discon-
tinuations among women than among men will not be fully
understood.
Limitations of the study include its open-label design, and the
fact that it was not speciﬁcally designed or powered to investi-
gate the inﬂuence of gender on outcomes. A larger number of
female patients would enable more meaningful comparisons
between the two treatment groups.
In summary, the results of this study show that atazanavir/
ritonavir is an effective once-daily boosted PI regimen that in
combination with other ARVs is well tolerated and appropriate
for use in HIV-infected women and men. The lower response
rates observed in women than in men may have been due to
higher discontinuation rates in women in both treatment arms,
suggesting the need for additional research to understand the
reasons why women are less likely to complete clinical trials.
Acknowledgements
Part of this research was presented as a poster at the Twelfth European
AIDS Conference, Cologne, Germany, 2009 (Poster PE7.3/8) and the
Twenty-second Annual Conference of the Association of Nurses in AIDS
Care, Jacksonville, FL, USA, 2009 (Poster P-18).
We thank the investigators, study coordinators, site and data
managers and patients for their contributions. We thank Victoria Wirtz
for contributions to the analyses and to the manuscript.
Funding
This study was supported by Bristol-Myers Squibb. Editorial support was
funded by Bristol-Myers Squibb.
Transparency declarations
K. E. S. has received research grant support from Biocryst, Gilead Sciences,
GlaxoSmithKline, Merck and Tibotec, and has served on scientiﬁc advisory
boards and received consultancy fees and/or honoraria from Gilead
Sciences, GlaxoSmithKline, Merck, Schering-Plough, Tibotec and
Squires et al.
368Tobira. M. J. has received honoraria from Bristol-Myers Squibb, Glaxo-
SmithKline, Tibotec, ViiV Healthcare, Abbott and MSD. R. Y., J. U.,
L. S. and D. M. are employees of and stockholders in Bristol-Myers
Squibb. J. A. was employed by Bristol-Myers Squibb at the time the
research was conducted.
C. Jenkins and J. Turner, of PAREXEL, provided assistance in preparing
and editing the manuscript.
Author contributions
D. M. and R. Y. provided scientiﬁc input into the study design and study
protocol. R. Y. did all the statistical analyses. All authors assessed clinical
data from the study and contributed to the drafting and editing of the
manuscript.
References
1 UNAIDS. 2008 Report on the Global HIV/AIDS Epidemic. http://www.
unaids.org/en/knowledgecentre/hivdata/globalreport/2008/2008_global_
report.asp (24 April 2010, date last accessed).
2 UNAIDS/WHO. AIDS Epidemic Update, 2009. http://data.unaids.org/
pub/Report/2009/JC1700_Epi_Update_2009_en.pdf (24 April 2010, date
last accessed).
3 Belden KA, Squires KE. HIV infection in women: do sex and gender
matter? Curr Infect Dis Rep 2008; 10: 423–31.
4 Pardo M, Ruiz M, Gimeno A. Gender bias in clinical trials of AIDS drugs.
In: Abstracts of the Fourteenth International AIDS Conference, Barcelona,
Spain, 2002. Abstract WePeB5964. http://gateway.nlm.nih.gov/gw/Cmd?
GMResultsSummary%261oc=nccs (25 October 2010, date last accessed).
5 Currier J, Averitt BD, Hagins D et al. Sex-based outcomes of darunavir-
ritonavir therapy: a single-group trial. Ann Intern Med 2010; 153: 349–57.
6 Fourie J, Flamm J, Rodriguez-French A. ARTEMIS: week 96 safety and
efﬁcacy of darunavir/r by gender, age and race. In: Abstracts of the
Fifth IAS Conference on HIV Pathogenesis, Treatment and Prevention,
Cape Town, South Africa, 2009. Abstract CDB072. http://library.iasociety.
org/AbstractView.aspx?confID=2009&abstractId=1831 (25 October
2010, date last accessed).
7 Walmsley SL, Squires K, Weiss L et al. Multidrug-experienced HIV-1-
infected women demonstrated similar virological and immunological
responses to tipranavir/ritonavir compared with men. AIDS 2009; 23:
429–31.
8 Absalon J, Uy J, Yang R et al. Gender-based differences in ARV-naive
patients treated with boosted protease inhibitors: results from the
CASTLE study (AI424138). In: Abstracts of the Seventeenth International
AIDS Conference, Mexico City, 2008. Abstract TUPE0062. http://www.
aids2008-abstracts.org/aids2008_book_vol1_web.pdf (25 October 2010,
date last accessed).
9 Moore AL, Kirk O, Johnson AM et al. Virologic, immunologic, and clinical
response to highly active antiretroviral therapy: the gender issue revisited.
J Acquir Immune Deﬁc Syndr 2003; 32: 452–61.
10 Murphy RL, Gulick RM, DeGruttola V et al. Treatment with amprenavir
alone or amprenavir with zidovudine and lamivudine in adults with
human immunodeﬁciency virus infection. AIDS Clinical Trials Group 347
Study Team. J Infect Dis 1999; 179: 808–16.
11 Tedaldi EM, Absalon J, Thomas AJ et al. Ethnicity, race, and gender.
Differences in serious adverse events among participants in an
antiretroviral initiation trial: results of CPCRA 058 (FIRST Study). J Acquir
Immune Deﬁc Syndr 2008; 47: 441–8.
12 Kumar PN, Rodriguez-French A, Thompson MA et al. A prospective,
96-week study of the impact of Trizivir, Combivir/nelﬁnavir, and
lamivudine/stavudine/nelﬁnavir on lipids, metabolic parameters and
efﬁcacy in antiretroviral-naive patients: effect of sex and ethnicity. HIV
Med 2006; 7: 85–98.
13 Dieleman JP, Jambroes M, Gyssens IC et al. Determinants of recurrent
toxicity-driven switches of highly active antiretroviral therapy. The
ATHENA cohort. AIDS 2002; 16: 737–45.
14 Panel on Antiretroviral Guidelines for Adults and Adolescents.
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected
Adults and Adolescents, December 1, 2009. http://www.aidsinfo.nih.
gov/ContentFiles/AdultandAdolescentGL.pdf (10 December 2009, date
last accessed).
15 Jacobs RJ, Kane MN. HIV-related stigma in midlife and older women.
Soc Work Health Care 2010; 49: 68–89.
16 Molina JM, Andrade-Villanueva J, Echevarria J et al. Once-daily
atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in
combination with tenofovir and emtricitabine, for management of
antiretroviral-naive HIV-1-infected patients: 48 week efﬁcacy and safety
results of the CASTLE study. Lancet 2008; 372: 646–55.
17 Molina JM, Andrade-Villaneuva J, Echevarria J et al. Once-daily
atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in
combination with tenofovir and emtricitabine, for management of
antiretroviral-naive HIV-1-infected patients: 96-week efﬁcacy and
safety results of the CASTLE study. J Acquir Immune Deﬁc Syndr 2010; 53:
323–32.
18 Third Report of the National Cholesterol Education Program (NCEP)
Expert Panel on Detection, Evaluation, and Treatment of High Blood
Cholesterol in Adults (Adult Treatment Panel III) ﬁnal report. Circulation
2002; 106: 3143–421.
19 Malan DR, Krantz E, David N et al. Efﬁcacy and safety of atazanavir,
with or without ritonavir, as part of once-daily highly active antire-
troviral therapy regimens in antiretroviral-naive patients. J Acquir
Immune Deﬁc Syndr 2008; 47: 161–7.
20 Elion R, Cohen C, Ward D et al. Evaluation of efﬁcacy, safety,
pharmacokinetics, and adherence in HIV-1-infected, antiretroviral-naive
patients treated with ritonavir-boosted atazanavir plus ﬁxed-dose
tenofovir DF/emtricitabine given once daily. HIV Clin Trials 2008; 9:
213–24.
21 Eron J Jr, Yeni P, Gathe J Jr et al. The KLEAN study of fosamprenavir-
ritonavir versus lopinavir-ritonavir, each in combination with abacavir-
lamivudine, for initial treatment of HIV infection over 48 weeks: a
randomised non-inferiority trial. Lancet 2006; 368: 476–82.
22 Ortiz R, DeJesus E, Khanlou H et al. Efﬁcacy and safety of once-daily
darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive
HIV-1-infected patients at week 48. AIDS 2008; 22: 1389–97.
23 Ananworanich J, Gayet-Ageron A, Ruxrungtham K et al. Long-term
efﬁcacy and safety of ﬁrst-line therapy with once-daily saquinavir/
ritonavir. Antivir Ther 2008; 13: 375–80.
24 Gathe J, da Silva B, Loutfy M. Study M05-730 primary efﬁcacy results
at week 48: phase 3, randomized, open-label study of lopinavir/ritonavir
tablets once daily vs twice daily, co-administered with tenofovir and
emtricitabine in ARV-naive HIV-1-infected subjects. In: Abstracts of the
Fifteenth Conference on Retrovirus and Opportunistic Infections, Boston,
MA, 2008. Abstract 775. http://www.retroconference.org/2008/PDFs/775.
pdf (25 October 2010, date last accessed).
25 da Silva BA, Cohen D, Gibbs S et al. Impact of gender on response to
lopinavir/ritonavir (LPV/r) tablets dosed QD or BID administered with
tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) in
antiretroviral-naı ¨ve (ARV) subjects: results from study M05-730. In:
Abstracts of the Seventeenth International AIDS Conference, Mexico City,
2008. Abstract TUPE0069. http://www.aids2008-abstracts.org/aids2008_
book_vol1_web.pdf (25 October 2010, date last accessed).
Comparative gender analysis: CASTLE study
369
JAC26 Hoffman RM, Umeh OC, Garris C et al. Evaluation of sex differences of
fosamprenavir (with and without ritonavir) in HIV-infected men and
women. HIV Clin Trials 2007; 8: 371–80.
27 Andrade-Villaneuva J, Herrera G, Chiliade P et al. ARTEMIS: week 48
safety and efﬁcacy of darunavir/r by gender, age and race. In: Abstracts
of the Seventeenth International AIDS Conference, Mexico City, 2008.
Abstract TUPE0064. http://www.aids2008-abstracts.org/aids2008_book_
vol1_web.pdf (25 October 2010, date last accessed).
28 Mocroft A, Gill MJ, Davidson W et al. Are there gender differences in
starting protease inhibitors, HAART, and disease progression despite
equal access to care? J Acquir Immune Deﬁc Syndr 2000; 24: 475–82.
29 Roberts KJ, Mann T. Barriers to antiretroviral medication adherence in
HIV-infected women. AIDS Care 2000; 12: 377–86.
30 Riddler SA, Haubrich R, DiRienzo AG et al. Class-sparing regimens
for initial treatment of HIV-1 infection. N Engl J Med 2008; 358:
2095–106.
31 Kaletra. [US prescribing information]. Chicago, IL: Abbott Laboratories;
2009.
32 Reyataz. [US prescribing information]. Princeton, NJ: Bristol-Myers
Squibb; 2009.
33 Zhang J, Chung E, Yones C et al. The effect of atazanavir/ritonavir on
the pharmacokinetics of an oral contraceptive containing ethinyl
estradiol and norgestimate in healthy women. Antivir Ther in press.
34 Gordillo V, Fekete EM, Platteau T et al. Emotional support and gender
in people living with HIV: effects on psychological well-being. J Behav Med
2009; 32: 523–31.
Squires et al.
370